Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.

Herantis Pharma logo

Find us on LinkedIn

 

  • Highlight

    Topline Phase 1b data webcast

  • Highlight

    Herantis Pharma Plc Half Year Report January 1 – June 30, 2025

  • Highlight

    H1/2025 Report webcast

  • Highlight

    Edison TV interview with Herantis CEO, Antti Vuolanto

Latest news and releases